Rigel Pharmaceuticals reported second quarter 2026 total revenues of $78.7 million and net income of $17.3 million, or $0.93 basic per share. Net product sales reached $67.0 million, driven by TAVALISSE ($47.4 million), GAVRETO ($10.7 million), and REZLIDHIA ($8.9 million). The company raised its full-year 2026 revenue guidance to approximately $285–$295 million. Rigel also announced the in-license of VEPPANU (vepdegestrant) from Arvinas and Pfizer, paying a $70.0 million upfront fee, with commercial availability expected in mid-August 2026. Additionally, Rigel appointed Alison L. Hannah as Executive Vice President and Chief Medical Officer. The company operates in the biotechnology industry, focusing on discovering and developing therapies for hematologic disorders and cancer.

Rigel Pharmaceuticals, Inc. announced leadership changes in its medical division. Alison L. Hannah, M.D., was appointed Executive Vice President and Chief Medical Officer effective July 1, 2026, upon which she resigned from the Board of Directors. Concurrently, Lisa Rojkjaer, M.D., separated from the company as Executive Vice President and Chief Medical Officer on June 25, 2026. Rigel Pharmaceuticals is a biotechnology company focused on developing therapies for various medical conditions.

Rigel Pharmaceuticals, Inc. completed the acquisition of exclusive, global rights to develop, manufacture, and commercialize VEPPANU™ (vepdegestrant) and related products worldwide through a License Agreement with Arvinas, Inc., Arvinas Operations, Inc., Arvinas Estrogen Receptor, Inc., and Pfizer Inc. The transaction, which involved a one-time upfront payment of $70.0 million, became effective following the satisfaction of all closing conditions and the Hart-Scott-Rodino Antitrust Improvements Act waiting period termination. Rigel Pharmaceuticals, Inc. is a biopharmaceutical company focused on small molecule drugs for various medical conditions.